Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: Special reference to the octreotide treatment

Neurological Research

Volumn 30, Issue 5, 2008, Pages 518-522

  Kurosaki, Masamichi ^a   Saeger, Wolfgang ^b   Abe, Takumi ^c   Lüdecke, Dieter K ^d  

^a TOTTORI UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c Institute of Pathology   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Acromegaly; Octreotide; Pituitary adenoma; VEGF

Indexed keywords

BROMOCRIPTINE; OCTREOTIDE; VASCULOTROPIN;

ADOLESCENT; ADULT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INVASION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; FEMALE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; PREOPERATIVE TREATMENT; PROTEIN EXPRESSION; RATING SCALE; SCHOOL CHILD; STAINING; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADENOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY GLAND; PITUITARY NEOPLASMS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TECHNOLOGY, RADIOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 47549085629     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313208X289499     Document Type: Article

References (33)

1. Barkan AL, Lloyd RV, Chandler WF, et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988; 67: 1040-1048
2. Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev 1988; 9: 417-436
3. Melmed S, Dowling H, Frohman L, et al. Consensus statement: Benefits versus risks of medical therapy for acromegaly. Am J Med 1994; 97: 468-473
4. Plockinger U, Reichel M, Fett U, et al. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: Effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 1994; 79: 1416-1423
5. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the international multicenter acromegaly study group. Arch Intern Med 1996; 151: 1573-1578
6. Abe T, Ludecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endcocrinol 2001; 145: 137-145
7. Colao A, Ferone D, Cappabianca P, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997; 82: 3308-3314
8. Fahlbusch R, Honegger J, Buchfelder M. Acromegaly-the place of the neurosurgeon. Metabolism 1996; 45: 65-66
9. Spinas GA, Zapf J, Landolt AM, et al. Preoperative treatment of 5 acromegalics with a somatostatin analogue: Endocrine and clinical observation. Acta Endocrinol 1987; 114: 249-256
10. Stevenaert A, Beckers A. Presurgical octreotide: Treatment in acromegaly. Metabolism 1996; 45: 72-74
11. Ezzat S, Horvath E, Harris AG, et al. Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab 1994; 79: 113-118
12. Kawamoto K, Uozumi T, Sakoda K, et al. Cytocidal effects of bromocriptine, somatostatin analog, and heat on growth hormone-secreting pituitary adenoma in vitro. Cancer 1992; 69: 2688-2696
13. Pelicci G, Pagliacci MC, Lanfrancone L, et al. Inhibitory effect of the somatostatin analog octreotide on rat pituitary tumor cell (GH3) proliferation in vitro. J Endocrinol Invest 1990; 13: 657-662
14. Saitoh Y, Arita N, Ohnishi T, et al. Absence of apoptosis in somatotropinomas treated with octreotide. Acta Neurochirurgica (Wien) 1997; 139: 851-856
15. Dvorak HF, Brown LF, Detmer M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular permeability and angiogenesis. Am J Pathol 1995; 146: 1029-1039
16. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36: 127-137
17. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25
18. Nicosia RF. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Commentary. Am J Pathol 1998; 153: 11-16
19. Berkmann RA, Merrill MJ, Reinhold WC, et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 1993; 91: 153-159
20. Cheng SY, Huang HJ, Nagane M, et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996; 93: 8502-8507
21. Fukui S, Nawashiro H, Otani N, et al. Vascular endothelial growth factor expression in pituitary adenomas. Acta Neurochir Suppl 2003; 86: 519-521
22. Hatva E, Kaipanien A, Mentula P, et al. Expression of endothelial cell-specific receptor tyrosine kinases and growth factor in human brain tumors. Am J Pathol 1995; 146: 368-378
23. Lloyd RV, Scheithauer BW, Kuroki T, et al. Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocri Pathol 1999; 10: 229-235
24. Morii K, Tanaka R, Washiyama, et al. Expression of vascular endothelial growth factor in capillary hemangioblastoma. Biochem Biophys Res Commun 1993; 194: 749-755
25. Nishikawa R, Cheng SY, Nagashima R, et al. Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol 1998; 96: 453-462
26. Niveiro M, Aranda FI, Peiro G, et al. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum Patol 2005; 36: 1090-1095
27. Pietsch T, Valter MM, Wolf HK, et al. Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 1997; 93: 109-117
28. Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995; 55: 1189-1193
29. Takata K, Yamada S, Teramoto A. Correlation between tumor vascularitiy and clinical findings in patients with pituitary adenomas. Endocr Pathol 2004; 15: 131-139
30. Viacava P, Gasperi M, Acerbi G, et al. Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest 2003; 26: 23-28
31. Wizigmann-Voos S, Breier G, Risau W, et al. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 1995; 55: 1358-1364
32. Ludecke DK. Value of transcavernous surgery in the treatment of pituitary adenomas. Eur J Endocrinol 1995; 133: 147-148
33. Vidal S, Oliveira MC, Kovacs K, et al. Immunolocalization of vascular endothelial growth factor in the GH3 cell line. Cell Tissue Res 2000; 300: 83-88